Opens in a new tab or window CHICAGO -- Neoadjuvant chemotherapy ... Surgery plus effective systemic therapy achieves the best outcomes in resectable pancreatic cancer, Labori noted.

“Previously, we needed to wait until after complex surgery to tell how the pancreatic cancer responded to the neoadjuvant therapy,” Abdelrahman said in a press release. “With FDG-PET we can ...

Perspective from Jashodeep Datta, MD CHICAGO — Neoadjuvant FOLFIRINOX chemotherapy failed to extend OS compared with upfront surgery for patients with resectable pancreatic head cancer ...

SAN DIEGO -- A preoperative combination of chemotherapy and immunotherapy (IO) appeared safe and effective for borderline resectable pancreatic cancer ... was to use neoadjuvant therapy to reduce ...

Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic ...

"This trial was initially designed to address the need for a more effective and tolerable adjuvant systemic therapy for pancreatic cancer ... for future adjuvant and neoadjuvant trials," Dr ...

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO ...

In a recent prospective observational cohort study published in eClinicalMedicine, researchers evaluated a modified regimen of total neoadjuvant treatment (TNT) in high-risk locally advanced ...

therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. The PANOVA-3 trial evaluated the use of TTFields ...